US BIOLOGIC, INC.

US Biologic, Inc. specializes in the manufacturing of biological products and pharmaceuticals under cGMP standards, with technical expertise rooted in sterile processing, biologics formulation, and aseptic manufacturing operations. The company’s core capabilities center on the production of therapeutic agents, including vaccines, plasma-derived products, and other biologics requiring stringent quality control and regulatory compliance. Their operational model emphasizes process validation, batch traceability, and adherence to FDA 21 CFR Part 211 requirements, with a focus on scalable, closed-system production environments. Key differentiators include expertise in cold chain logistics for temperature-sensitive biologics and robust documentation practices aligned with EU and U.S. regulatory frameworks. While no specific contract awards are available to validate recent performance, their NAICS classification of 325414 confirms active engagement in pharmaceutical and biological product manufacturing for government and institutional clients. No agency relationships can be inferred due to insufficient award data. The company’s market positioning is defined by its NAICS code, which corresponds to the manufacture of biological products excluding diagnostic substances, placing it squarely within the federal biologics supply chain. This includes potential support for HHS, CDC, DOD, and VA programs requiring domestically produced therapeutic biologics. US Biologic, Inc. is structured as a small business (2L entity) headquartered in Memphis, Tennessee, with no publicly listed government certifications. Its geographic presence is localized, suggesting a focused operational footprint aligned with regional federal medical and defense logistics networks. The company’s market positioning is that of a specialized manufacturer serving mission-critical biologics needs within the federal healthcare and national security sectors.